Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-valent HPV vaccine (Hansenula Polymorpha) in Chinese females 16-26
NCT05372016Phase 3Completed
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine (Hansenula polymorpha) in human papillomavirus infection, sponsored by Shanghai Bovax Biotechnology Co., Ltd.. Started Sep 2020; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine (Hansenula polymorpha)
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05372016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372016.